Improved overall survival after the addition of rituximab to chemotherapy alone as first-line therapy for mantle cell lymphoma (MCL): Evidence from SEER-Medicare.
M. H. Dreyling
Consultant or Advisory Role - Roche
Honoraria - Roche
Research Funding - Roche
R. Griffiths
Consultant or Advisory Role - Genentech
M. Gleeson
Consultant or Advisory Role - Genentech
M. Danese
Consultant or Advisory Role - Genentech
J. Mikhael
No relevant relationships to disclose